The Extent to Which Lipid Nanoparticles Require Apolipoprotein E and Low-Density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid Structure.
The Extent to Which Lipid Nanoparticles Require Apolipoprotein E and Low-Density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid Structure.
复制标题
脂质纳米颗粒需要载脂蛋白 E 和低密度脂蛋白受体进行递送的程度随可电离脂质结构的变化而变化。
DOI:
10.1021/acs.nanolett.2c03741
复制
发表时间:
2022
期刊:
影响因子:
10.8
通讯作者:
Dahlman,JamesE
中科院分区:
文献类型:
--
作者:
Paunovska,Kalina;DaSilvaSanchez,AlejandroJ;Lokugamage,MelissaP;Loughrey,David;Echeverri,ElisaSchrader;Cristian,Ana;Hatit,MarineZC;Santangelo,PhilipJ;Zhao,Kun;Dahlman,JamesE
Lipid nanoparticles (LNPs) have delivered therapeutic RNA to hepatocytes in humans. Adsorption of apolipoprotein E (ApoE) onto these clinical LNP-mRNA drugs has been shown to facilitate hepatocyte entry via the low-density lipoprotein receptor (LDLR). Since ApoE-LDLR trafficking is conserved in mice, non-human primates, and humans, characterizing this mechanism eased clinical transition. Recently, LNPs have delivered mRNA to non-hepatocytes in mice and non-human primates, suggesting they can target new cell types via ApoE- and LDLR-independent pathways. To test this hypothesis, we quantified how 60 LNPs delivered mRNA with cell type resolution in wild-type mice and three knockout mouse strains related to lipid trafficking: ApoE–/–, LDLR–/–, and PCSK9–/–. These data suggest that the hydrophobic tail length of diketopiperazine-based lipids can be changed to drive ApoE- and LDLR-independent deliveryin vivo. More broadly, the results support the hypothesis that endogenous LNP trafficking can be tuned by modifying lipid chemistry.